Acyl-CoA Synthetase Short-Chain: Potential Drug Target Or Biomarker

Target Name: Acyl-CoA Synthetase Short-Chain

NCBI ID: P12326

Other Name(s): Acetate--CoA ligase | ACSS

Acyl-CoA Synthetase Short-Chain: Potential Drug Target Or Biomarker

Acyl-CoA Synthetase Short-Chain (nonspecified subtype), also known as Acetate--CoA ligase, is an enzyme involved in the citric acid cycle (also known as the Krebs cycle or TCA cycle) in all eukaryotic cells. This cycle is a central metabolic pathway that generates energy through the production of ATP, NADH, and FADH2, as well as the production of various molecules, including aromatic amino acids, such as tryptophan and tyrosine, which are important for cell growth and signaling.

The acyl-CoA synthetase short-chain is a critical enzyme in the citric acid cycle, as it catalyzes the final step in the synthesis of acyl-CoA, which is the key step in the production of fatty acids and the starting point for the citric acid cycle. The acyl-CoA synthetase short-chain is a nonspecific enzyme that can catalyze the synthesis of acyl-CoA from various precursors, including malate, succinate, or fumarate.

The acyl-CoA synthetase short-chain is also a potential drug target or biomarker, as it has been shown to play a role in various cellular processes, including cell growth, differentiation, and metabolism. The acquisition of acyl-CoA synthetase short-chain knockdown in various organisms has been shown to result in a variety of cellular and behavioral changes, including increased cell proliferation, reduced differentiation, and increased sensitivity to various stimuli.

In addition to its role in cellular metabolism, the acyl-CoA synthetase short-chain has also been shown to play a role in various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. For example, acyl-CoA synthetase short-chain knockdown has been shown to reduce the sensitivity of cancer cells to chemotherapy, and to increase the lifespan of animals with neurodegenerative diseases.

The acyl-CoA synthetase short-chain is also a potential biomarker for certain metabolic disorders, such as phenylketonuria (PKU), a genetic disorder that is characterized by the inability to break down certain phenylalanine molecules. PKU patients are unable to synthesize certain amino acids, including tryptophan and tyrosine, which are synthesized from the acyl-CoA synthetase short-chain, and as a result, they are unable to produce normal levels of these molecules.

The acyl-CoA synthetase short-chain is also involved in the production of aromatic amino acids, which are important for the structure and function of various molecules, including proteins, nucleic acids, and signaling molecules. The production of aromatic amino acids from the acyl-CoA synthetase short-chain is a critical step in the production of these molecules, and as a result, the acyl-CoA synthetase short-chain has been shown to play a role in the regulation of various cellular processes, including cell growth, differentiation, and metabolism.

In conclusion, the acyl-CoA synthetase short-chain is a nonspecific enzyme that is involved in the citric acid cycle and the production of fatty acids. Its acquisition has been shown to result in a variety of cellular and behavioral changes, including increased cell proliferation, reduced differentiation, and increased sensitivity to various stimuli. The acyl-CoA synthetase short-chain is also a potential drug target or biomarker, and has been shown to play a role in various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. Its role in the production of aromatic amino acids also suggests that it may have implications for the regulation of various cellular processes, including cell growth, differentiation, and metabolism. Further research is needed to fully understand the role of the acyl-CoA synthetase short-chain in cellular

Protein Name: Acyl-CoA Synthetase Short-Chain (nonspecified Subtype)

More Common Targets